Utah Medical Cannabis Program Surpasses 110,000 Active Patients, February Sales Top $15 Million
- Utah’s medical marijuana program surpassed 110,000 active patients in early March, supported by over 1,000 medical providers and nearly 3,000 agents across various roles.
- Salt Lake County leads patient numbers with 45,898, followed by Utah, Davis, and Weber counties, showing program concentration along the Wasatch Front.
- Most patients are aged 31-40 (26.17%), with persistent pain as the predominant qualifying condition reported by 95,946 patients.
- February sales reached $15 million, led by cartridges and vape pens, while cultivators harvested over 9,200 plants producing 8 million grams of cannabis biomass.
Utah’s medical marijuana program continued its steady expansion in February, with active patient counts surpassing 110,000 according to the state’s latest report. As of early March, Utah had 110,487 patients with active medical cannabis cards. The program also includes 1,022 registered recommending medical providers, 181 paper-only providers, 894 processor and cultivator agents, 919 pharmacy agents, 419 courier agents, and 96 pharmacy medical providers.
Salt Lake County remains the epicenter of the program, accounting for 45,898 patients, followed by Utah County with 16,819 and Davis County with 12,168. Weber County also tops 11,000 patients, highlighting continued concentration along the Wasatch Front.
The majority of patients are between the ages of 31 and 40, representing 26.17% of the total. Those aged 41 to 50 make up 22.40%, followed closely by 21 to 30 at 21.92%. Patients 51 to 64 account for 18.41%, while those over 65 represent 11.03%. Individuals under 21 comprise well under 1% of the program.
Persistent pain remains by far the most common qualifying condition, with 95,946 patients listing it. PTSD is reported by 5,709 patients, cancer by 2,092, nausea by 2,411, epilepsy by 737, Crohn’s disease by 585, and multiple sclerosis by 722. Other conditions each account for a relatively small share of total participants.
Purchasing activity remains strong. In the past 30 days alone, 60,594 patients made at least one purchase, with 33,988 making two or more. Over a 90-day period, 84,384 patients made at least one purchase, and 41,401 made four or more purchases, indicating steady engagement across the patient base.
Cartridges and vape pens were the top-selling category in February, generating $7,240,000 in sales. Flower followed at $4,844,100, while infused edibles reached $2,702,300. Infused non-edible products accounted for $110,800, and non-medicated accessories such as devices and batteries brought in $127,100. Combined, there was $15,024,300 in medical cannabis sales in February.
On the production side, cultivators harvested more than 9,245 plants during February, producing over 8,019,991 grams of wet cannabis biomass across 232 planting batches. Processors also sent 140,508 cartridges and pens, 101,414 units of flower, and 88,070 infused edible products to pharmacies during the month.
The February figures reflect a stable and well-utilized medical marijuana program, with sustained patient participation and strong demand across multiple product categories.